St. Franziskus-Hospital GmbH
- Address
- lock Available on a paid plan
Diagnostic Imaging Research
At St. Franziskus-Hospital GmbH, the Klinik für Radiologie is involved in research focused on Analytical, Diagnostic and Therapeutic Techniques and Equipment, with an emphasis on improving diagnosis through advanced imaging tools. One major area of interest is the evaluation of contrast enhancement in magnetic resonance imaging for people with suspected or known central nervous system pathology, aiming to assess whether newer contrast agents can provide reliable imaging performance and safety.
- Improving MRI contrast quality for clearer diagnostic imaging
- Evaluating the safety and effectiveness of new contrast agents
- Supporting better assessment of brain and spinal cord disorders
This research reflects a practical focus on making imaging more accurate and dependable for everyday clinical decision-making.
Ophthalmology and Retina Studies
The site also contributes to research in Eye Diseases, especially exudative age-related macular degeneration and related retinal complications. These studies are designed to test whether new treatment approaches can better manage submacular haemorrhage and improve vision-related outcomes compared with standard anti-VEGF treatment alone.
- Studying treatment options for wet AMD and submacular haemorrhage
- Comparing combination approaches with standard anti-VEGF care
- Exploring ways to improve outcomes for patients with retinal disease
This work highlights a strong interest in refining therapies for complex retinal conditions where preserving vision is a major goal.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 28 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in St. Franziskus-Hospital GmbH
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21181) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of the central nervous system (CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 28 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Anastrozole | 2 | Unknown | 2021-05-11 | 2022-10-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.